Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Quality of life
RCT 4-armed trial	229 people with plaque psoriasis involving at least 10% of body surface area Further report of reference	Mean improvement from baseline on Dermatology Life Quality Index (DLQI) scale (from 0 to 30) 12 weeks after the end of treatment 4.0 with alefacept 0.025 mg/kg 4.4 with alefacept 0.075 mg/kg 3.2 with alefacept 0.150 mg/kg 1.7 with placebo Absolute results reported graphically	P = 0.04 for alefacept at any dose v placebo However, the clinical importance of these results is difficult to assess (see further information on studies)	Effect size not calculated	alefacept at any dose
RCT	553 people with plaque psoriasis involving at least 10% of body surface area Further report of reference	Mean improvement from baseline on DLQI scale (from 0 to 30) 2 weeks after treatment 4.4 with intravenous alefacept 7.5 mg once weekly for 12 weeks 1.8 with placebo for 12 weeks	P <0.0001 However, the clinical importance of these results is difficult to assess	Effect size not calculated	alefacept
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area Further report of reference	Mean improvement in DLQI score from baseline (scale from 0 to 30) 2 weeks after end of treatment 4.9 with intramuscular alefacept 15 mg once weekly 2.7 with placebo once weekly Absolute numbers not reported	P <0.001 for alefacept (15 mg) v placebo However, the clinical importance of these results is difficult to assess	Effect size not calculated	alefacept 15 mg
RCT 3-armed trial	507 people with chronic plaque psoriasis involving a mean 21% of body surface area Further report of reference	Mean improvement in DLQI score from baseline (scale from 0 to 30) 2 weeks after end of treatment 3.8 with intramuscular alefacept 10 mg once weekly 2.7 with placebo once weekly	P reported as not significant for alefacept 10 mg v placebo However, the clinical importance of these results is difficult to assess		Not significant